Abstract
Phospholipases A2 (PLA2) are enzymes of high medical scientific interest due to their involvement in a large number of human inflammatory diseases. PLA2 constitute a diverse family of enzymes which catalyses the hydrolysis of the sn-2 ester bond in glycerophospholipids and exhibit a wide range of physiological and pathological effects. The ubiquitous nature of PLA2 highlights the important role they play in many biological processes, as cell signaling and cell growth, including the generation of proinflammatory lipid mediators such as prostaglandin and leukotrienes, regulation of lipid mediators. The activity and expression of several PLA2 isoforms are increased in several human cancers, suggesting that these enzymes have a central role in both tumor development and progression and can be targets for anti-cancer drugs. On the other hand, some PLA2 isolated from Viperidae venoms are capable to induce antitumoral activity. In summary PLA2 from snake venoms can be a new class of anticancer agents and provide new molecular and biological insights of cancer development.
Keywords: Snake venom, phospholipase A2, antitumor effect, VRCTC-310
Protein & Peptide Letters
Title: Snake Venom Phospholipases A2: A New Class of Antitumor Agents
Volume: 16 Issue: 8
Author(s): Renata S. Rodrigues, Luiz Fernando M. Izidoro, Robson J. de Oliveira Jr., Andreimar M. Soares, Veridiana M. Rodrigues and Suely V. Sampaio
Affiliation:
Keywords: Snake venom, phospholipase A2, antitumor effect, VRCTC-310
Abstract: Phospholipases A2 (PLA2) are enzymes of high medical scientific interest due to their involvement in a large number of human inflammatory diseases. PLA2 constitute a diverse family of enzymes which catalyses the hydrolysis of the sn-2 ester bond in glycerophospholipids and exhibit a wide range of physiological and pathological effects. The ubiquitous nature of PLA2 highlights the important role they play in many biological processes, as cell signaling and cell growth, including the generation of proinflammatory lipid mediators such as prostaglandin and leukotrienes, regulation of lipid mediators. The activity and expression of several PLA2 isoforms are increased in several human cancers, suggesting that these enzymes have a central role in both tumor development and progression and can be targets for anti-cancer drugs. On the other hand, some PLA2 isolated from Viperidae venoms are capable to induce antitumoral activity. In summary PLA2 from snake venoms can be a new class of anticancer agents and provide new molecular and biological insights of cancer development.
Export Options
About this article
Cite this article as:
Rodrigues S. Renata, Izidoro M. Luiz Fernando, de Oliveira Jr. J. Robson, Soares M. Andreimar, Rodrigues M. Veridiana and Sampaio V. Suely, Snake Venom Phospholipases A2: A New Class of Antitumor Agents, Protein & Peptide Letters 2009; 16 (8) . https://dx.doi.org/10.2174/092986609788923266
DOI https://dx.doi.org/10.2174/092986609788923266 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
Call for Papers in Thematic Issues
Therapeutic Proteins and Peptides of Plant Origin
Plants are still the major repository of biologically active substances. In the last two decades, however, natural peptides and proteins of plant origin have gained increasing attention due to their pharmacological activities over a variety of human illnesses, including those mediated by infections and parasitosis and those involving different cellular ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in Osteosarcoma Treatment
Current Pharmaceutical Design Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Structural Basis and Therapeutic Implication of the Interaction of CCN Proteins with Glycoconjugates
Current Pharmaceutical Design Notochordal Nucleus Pulposus Cells: Prospective Strategies for Intervertebral Disc Repair and Regeneration
Current Tissue Engineering (Discontinued) Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Intraarticular Treatments for Osteoarthritis: New Perspectives
Current Drug Targets New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry LncRNAs as Therapeutic Targets for Autophagy-involved Cardiovascular Diseases: A Review of Molecular Mechanism and T herapy Strategy
Current Medicinal Chemistry Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology
Current Pharmaceutical Biotechnology miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Current Medicinal Chemistry Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design The Correspondence Between Magnetic Resonance Images and the Clinical and Intraoperative Status of Patients with Spinal Tumors
Current Medical Imaging